Transcatheter aortic valve implantation

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the January 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). A favourable opinion was issued on the add-on reimbursement for one new device, as well as on the extension of indications for two devices for transcatheter aortic valve implantation.

As of October 2025, the Dutch Healthcare Institute (ZIN) is working on coverage positions in several areas, including otorhinolaryngology, neurology, dental surgery, cardiovascular, and oncology fields.

In August 2025, the National Institute for Health and Care Excellence (NICE) published three new Late Stage Assessments on transcatheter heart valves for TAVI, bed frames in acute medical or surgical hospital wards, and compression products for venous leg ulcers.

In June 2025, Belgian INAMI/RIZIV updated the List of implants and invasive medical devices. Four new reimbursement codes were added to the List in relation to heart valve replacement. Several Nominative lists of brands were updated as well in the fields of neuromodulation, neurovascular, orthopedic, and cardiovascular.

In June 2025, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedures Guidance (TAVI in native aortic valve regurgitation, targeted muscle reinnervation for limb amputation pain, laparoscopic insertion of inactive implant for GERD). Furthermore, three clinical guidelines were updated.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in March 2024. Twelve recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, neurovascular, ENT, and surgical devices, interventional radiology and endoscopy procedures, as well as medical aids.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in February 2024. Fourteen recommendations were published concerning the registration of medical devices or modification of registration conditions with the extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, neurovascular, neuromodulation, endocrine, and endoscopy devices, as well as medical aids.

On June 19, 2023, the Swiss Federal Office of Public Health (FOPH) published the changes that will occur to the Healthcare Benefit Ordinance (KLV/OPre) and its Annexes, which determines coverage of medical services in Switzerland. Key changes relate to introduction of two codes for genetic tests, several extensions of Coverage with Evidence Development, and updates in reimbursement conditions for transcatheter aortic valve implantation. The changes entered into force on July 1, 2023.

In February 2023, NHS England released the position statement on Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR) for symptomatic, severe aortic stenosis in adults to support elective performance. Previously, NHS England was commissioning TAVI at high surgical risk. This new position statement sets criteria for intermediate and low-surgical risk patients who are eligible for TAVI.

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in October 2022. Fourteen recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular, neurovascular, orthopedic, and ENT devices, as well as medical aids.

In November 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (percutaneous implantation of pulmonary artery pressure sensors in chronic heart failure and coronary sinus narrowing device implantation for refractory angina), one new Medical Technologies Guidance (Synergo for non-muscle-invasive bladder cancer), one new Diagnostic Guidance (SeHCAT for diagnosing bile acid diarrhea), and four new Medtech Innovation Briefings (clonoSEQ for minimal residual disease, CerebAir for continuous EEG monitoring, 24/7 EEG SubQ for epilepsy, Paige Prostate for prostate cancer). Also, three new clinical guidelines were published, and six were updated.

In early-mid November 2021, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for two new cardiovascular technologies (Revivent TC™ by BioVentrix and Trilogy™ Heart Valve System by JenaValve Technology) in heart failure, and aortic valve insufficiency and stenosis, respectively.